Table 1.
Main associations between HLA-A*0101, HLA-B*0801, HLA-DR*0301 and TNF with all NHL and NHL subtypes (DLBCL, follicular, marginal zone, SLL/CLL and T-cell lymphomas) among non-Hispanic Caucasians, adjusted for age, sex and study center.
| Allele or haplotype* | Control n (%) | NHL n (%) | OR (95%CI) | DLBCL n (%) | OR (95%CI) | Follicular n (%) | OR (95%CI) | Marginal Zone n (%) | OR (95%CI) | CLL/SLL n (%) | OR (95%CI) | T cell n (%) | OR (95%CI) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HLA-A*01-B*08-DR*03 | |||||||||||||
| − | 438 (87) | 455 (84) | 1.0 (ref) | 123 (81) | 1.0 (ref) | 128 (86) | 1.0 (ref) | 36 (80) | 1.0 (ref) | 71 (87) | 1.0 (ref) | 28 (82) | 1.0 (ref) |
| + | 67 (13) | 88 (16) | 1.21 (0.89–1.78) | 29 (19) | 1.59 (0.98–2.59) | 21 (14) | 1.05 (0.61–1.80) | 9 (20) | 1.65 (0.75–3.61) | 11 (13) | 0.97 (0.48–1.94) | 6 (18) | 1.28 (0.49–3.28) |
| HLA-A*0101 | |||||||||||||
| − | 373 (70) | 389 (67) | 1.0 (ref) | 107 (65) | 1.0 (ref) | 108 (67) | 1.0 (ref) | 30 (64) | 1.0 (ref) | 58 (71) | 1.0 (ref) | 25 (69) | 1.0 (ref) |
| + | 162 (30) | 188 (33) | 1.12 (0.88–1.45) | 58 (35) | 1.28 (0.88–1.86) | 54 (33) | 1.19 (0.81–1.74) | 17 (36) | 1.35 (0.72–2.54) | 24 (29) | 0.96 (0.57–1.61) | 11 (31) | 1.07 (0.51–2.29) |
| HLA-B*0801 | |||||||||||||
| − | 435 (81) | 432 (70) | 1.0 (ref) | 120 (73) | 1.0 (ref) | 121 (74) | 1.0 (ref) | 34 (72) | 1.0 (ref) | 64 (78) | 1.0 (ref) | 28 (74) | 1.0 (ref) |
| + | 102 (19) | 148 (25) | 1.45 (1.09–1.94) | 45 (27) | 1.63 (1.08–2.45) | 42 (26) | 1.42 (0.93–2.17) | 13 (28) | 1.69 (0.85–3.33) | 18 (22) | 1.18 (0.67–2.09) | 10 (26) | 1.50 (0.69–3.26) |
| HLA-DR*0301 | |||||||||||||
| − | 415 (80) | 405 (74) | 1.0 (ref) | 110 (72) | 1.0 (ref) | 113 (75) | 1.0 (ref) | 28 (62) | 1.0 (ref) | 65 (79) | 1.0 (ref) | 24 (67) | 1.0 (ref) |
| + | 105 (20) | 145 (26) | 1.41 (1.06–1.88) | 43 (28) | 1.55 (1.02–2.36) | 38 (25) | 1.30 (0.83–2.00) | 17 (38) | 2.47 (1.29–4.71) | 17 (21) | 1.04 (0.58–1.86) | 12 (33) | 1.91 (0.90–4.04) |
| TNF G-308A | |||||||||||||
| GG | 383 (73) | 375 (67) | 1.0 (ref) | 98 (61) | 1.0 (ref) | 107 (69) | 1.0 (ref) | 29 (63) | 1.0 (ref) | 64 (80) | 1.0 (ref) | 22 (58) | 1.0 (ref) |
| GA | 130 (25) | 170 (30) | 1.33 (1.02–1.75) | 56 (35) | 1.72 (1.17–2.54) | 44 (28) | 1.19 (0.79–1.79) | 16 (35) | 1.61 (0.84–3.09) | 16 (20) | 0.70 (0.39–1.27) | 14 (37) | 1.77 (0.86–3.66) |
| AA | 12 (2) | 16 (3) | 1.45 (0.67–3.14) | 7 (4) | 2.37 (0.90–6.27) | 4 (3) | 1.17 (0.36–3.79) | 1 (2) | 1.23 (0.15–9.78) | — | — | 2 (5) | 2.95 (0.57–15.3) |
| GA/AA | 142 (27) | 186 (33) | 1.34 (1.03–1.75) | 63 (39) | 1.78 (1.22–2.59) | 48 (31) | 1.19 (0.80–1.77) | 17 (37) | 1.58 (0.83–3.00) | 16 (20) | 0.65 (0.36–1.18) | 16 (42) | 1.87 (0.93–3.75) |
| HLA-A*01-B*08-DR*03-TNF-A | |||||||||||||
| − | 425 (87) | 441 (84) | 1.0 (ref) | 120 (81) | 1.0 (ref) | 121 (85) | 1.0 (ref) | 36 (82) | 1.0 (ref) | 69 (87) | 1.0 (ref) | 28 (82) | 1.0 (ref) |
| + | 62 (13) | 82 (18) | 1.27 (0.89–1.82) | 28 (19) | 1.65 (1.00–2.72) | 21 (15) | 1.17 (0.68–2.01) | 8 (18) | 1.57 (0.69–3.56) | 19 (13) | 0.96 (0.46–1.98) | 6 (18) | 1.33 (0.52–3.45) |
Abbreviations: CI, confidence intervals; DLBCL, diffuse large B-cell lymphoma; HLA, human leukocyte antigen; NHL, non-Hodgkin lymphoma; OR, odds ratios; TNF, tumor necrosis factor; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma.
*
Numbers are not equivalent for each allele because of their differential genotyping completion rates. Results with P<0.05 are indicated in bold font.